Therefore, dissecting these relevant clinical findings and understanding how other signaling pathways impinge on PI3K/Akt/mTOR signaling pathway activity may provide us new clues as to how to effectively inhibit this pathway with potential candidate combination strategies to eradicate LSCs and so cure AML. The gene discussed is PIK3CD; the disease is acute myeloid leukemia.